AGL 40.00 No Change ▼ 0.00 (0%)
AIRLINK 129.06 Decreased By ▼ -0.47 (-0.36%)
BOP 6.75 Increased By ▲ 0.07 (1.05%)
CNERGY 4.49 Decreased By ▼ -0.14 (-3.02%)
DCL 8.55 Decreased By ▼ -0.39 (-4.36%)
DFML 40.82 Decreased By ▼ -0.87 (-2.09%)
DGKC 80.96 Decreased By ▼ -2.81 (-3.35%)
FCCL 32.77 No Change ▼ 0.00 (0%)
FFBL 74.43 Decreased By ▼ -1.04 (-1.38%)
FFL 11.74 Increased By ▲ 0.27 (2.35%)
HUBC 109.58 Decreased By ▼ -0.97 (-0.88%)
HUMNL 13.75 Decreased By ▼ -0.81 (-5.56%)
KEL 5.31 Decreased By ▼ -0.08 (-1.48%)
KOSM 7.72 Decreased By ▼ -0.68 (-8.1%)
MLCF 38.60 Decreased By ▼ -1.19 (-2.99%)
NBP 63.51 Increased By ▲ 3.22 (5.34%)
OGDC 194.69 Decreased By ▼ -4.97 (-2.49%)
PAEL 25.71 Decreased By ▼ -0.94 (-3.53%)
PIBTL 7.39 Decreased By ▼ -0.27 (-3.52%)
PPL 155.45 Decreased By ▼ -2.47 (-1.56%)
PRL 25.79 Decreased By ▼ -0.94 (-3.52%)
PTC 17.50 Decreased By ▼ -0.96 (-5.2%)
SEARL 78.65 Decreased By ▼ -3.79 (-4.6%)
TELE 7.86 Decreased By ▼ -0.45 (-5.42%)
TOMCL 33.73 Decreased By ▼ -0.78 (-2.26%)
TPLP 8.40 Decreased By ▼ -0.66 (-7.28%)
TREET 16.27 Decreased By ▼ -1.20 (-6.87%)
TRG 58.22 Decreased By ▼ -3.10 (-5.06%)
UNITY 27.49 Increased By ▲ 0.06 (0.22%)
WTL 1.39 Increased By ▲ 0.01 (0.72%)
BR100 10,445 Increased By 38.5 (0.37%)
BR30 31,189 Decreased By -523.9 (-1.65%)
KSE100 97,798 Increased By 469.8 (0.48%)
KSE30 30,481 Increased By 288.3 (0.95%)

Abbott Laboratories' first-quarter profit and sales beat analysts' estimates on Wednesday but some investors were disappointed as the healthcare company maintained its full-year profit forecast. The company's shares were down about 2 percent in early trading.
"It's all about the expectations," Evercore ISI analyst Vijay Kumar said, adding that some investors may have been expecting the company to raise its full-year earnings forecast. The company reiterated its FY 2018 forecast of adjusted earnings from continuing operation between $2.80 to $2.90 per share.
Abbott's first-quarter results were mainly helped by launches of new medical devices and a turnaround in its business that sells baby and adult nutritional supplements. Sales in the nutrition business, known for brands such as Similac and PediaSure, have been hemmed in since mid-2016, when China made it mandatory for manufacturers to re-register baby formulae with the government.
Quarterly sales at the unit increased 4.7 percent on an organic basis to $1.76 billion, above consensus estimates of $1.72 million, compiled by Cowen. The company reported net earnings of $418 million, or 23 cents per share, in the quarter ended March 31, compared to $419 million, or 24 cents per share, a year earlier.
Profit from Abbott's medical device business - its largest division - continued to benefit from its $25 billion purchase of St. Jude Medical, and from new device launches. Sales for the unit rose 14.6 percent to $2.74 billion in the quarter. "With the integration of Alere and St. Jude Medical well underway, debt repayment progressing, and a slew of new product launches already making a splash, Abbott continues to impress in 2018," BMO Capital Markets analyst Joanne Wuensch said.
Net sales rose to $7.39 billion from $6.34 billion. Excluding items, Abbott reported a profit of 59 cents per share. Analysts on average had expected profit of 58 cents per share on revenue of $7.29 billion, according to Thomson Reuters I/B/E/S.

Copyright Reuters, 2018

Comments

Comments are closed.